These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 9794562

  • 21. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
    Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM.
    Nephrol Dial Transplant; 2001 Jun; 16(6):1239-44. PubMed ID: 11390726
    [Abstract] [Full Text] [Related]

  • 22. Do two intravenous iron sucrose preparations have the same efficacy?
    Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A.
    Nephrol Dial Transplant; 2011 Oct; 26(10):3262-7. PubMed ID: 21355067
    [Abstract] [Full Text] [Related]

  • 23. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
    Takasawa K, Takaeda C, Wada T, Ueda N.
    Nutrients; 2018 Mar 29; 10(4):. PubMed ID: 29596361
    [Abstract] [Full Text] [Related]

  • 24. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A, Karkar A, Abdelrahman M.
    Saudi J Kidney Dis Transpl; 2007 Mar 29; 18(1):73-8. PubMed ID: 17237895
    [Abstract] [Full Text] [Related]

  • 25. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
    Canavese C, Bergamo D, Ciccone G, Burdese M, Maddalena E, Barbieri S, Thea A, Fop F.
    Nephrol Dial Transplant; 2004 Jun 29; 19(6):1564-70. PubMed ID: 15004263
    [Abstract] [Full Text] [Related]

  • 26. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.
    Li H, Wang SX.
    Perit Dial Int; 2008 Jun 29; 28(2):149-54. PubMed ID: 18332450
    [Abstract] [Full Text] [Related]

  • 27. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
    Nguyen TV.
    Am J Health Syst Pharm; 2009 Jun 15; 66(12):1101-4. PubMed ID: 19498125
    [Abstract] [Full Text] [Related]

  • 28. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, FIND-CKD Study Investigators.
    Nephrol Dial Transplant; 2014 Nov 15; 29(11):2075-84. PubMed ID: 24891437
    [Abstract] [Full Text] [Related]

  • 29. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
    Stancu S, Bârsan L, Stanciu A, Mircescu G.
    Clin J Am Soc Nephrol; 2010 Mar 15; 5(3):409-16. PubMed ID: 20019121
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
    Bovy C, Gothot A, Delanaye P, Warling X, Krzesinski JM, Beguin Y.
    Nephrol Dial Transplant; 2007 Apr 15; 22(4):1156-62. PubMed ID: 17237481
    [Abstract] [Full Text] [Related]

  • 33. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J.
    Am J Kidney Dis; 1999 Mar 15; 33(3):471-82. PubMed ID: 10070911
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y, Miyazaki S, Hirasawa Y, Gejyo F, Suzuki M.
    Kidney Int; 2003 Mar 15; 63(3):1086-93. PubMed ID: 12631092
    [Abstract] [Full Text] [Related]

  • 36. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
    Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K.
    Nephrol Dial Transplant; 2000 Nov 15; 15(11):1827-34. PubMed ID: 11071973
    [Abstract] [Full Text] [Related]

  • 37. Safety of intravenous injection of iron saccharate in haemodialysis patients.
    Sunder-Plassmann G, Hörl WH.
    Nephrol Dial Transplant; 1996 Sep 15; 11(9):1797-802. PubMed ID: 8918625
    [Abstract] [Full Text] [Related]

  • 38. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
    Braun J, Lindner K, Schreiber M, Heidler RA, Hörl WH.
    Nephrol Dial Transplant; 1997 Jun 15; 12(6):1173-81. PubMed ID: 9198047
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
    Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB.
    Am J Kidney Dis; 2001 Feb 15; 37(2):300-7. PubMed ID: 11157370
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.